Skip to main content
Log in

Complete response of esophageal small cell carcinoma amrubicin treatment

  • Case Report
  • Published:
Journal of Infection and Chemotherapy

Abstract

Small cell carcinoma of the esophagus (SmCCE) is a rare and aggressive disease known to have a poor prognosis. SmCCE patients are generally treated with a chemotherapeutic regimen for small cell lung cancer. Salvage therapy for patients with relapsed or refractory tumors has not yet been established. A 63-year-old man with extensive SmCCE was treated with chemotherapy consisting of cisplatin (CDDP) and irinotecan (CPT-11). After the second course of CPT-11/CDDP, the celiac lymph node increased in size. Amrubicin (AMR) as second-line chemotherapy was started. The patient had a complete response after the fifth course of AMR, resulting in an 8-month progression-free survival after initial administration. This case suggests that, as in small cell lung cancer, AMR is effective for SmCCE.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4
Fig. 5
Fig. 6
Fig. 7

References

  1. The Japanese Society for Esophageal Diseases. Comprehensive registry of esophageal cancer in Japan (1995, 1996, 1997), 2nd ed. 2001.

  2. The Japanese Society for Esophageal Diseases. Comprehensive registry of esophageal cancer in Japan (1998, 1999), 3rd ed. Tokyo: Japanese Society for Esophageal Diseases; 2002.

  3. Beyer KL, Marshall JB, Diaz-Arias AA, Loy TS. Primary small-cell carcinoma of the esophagus. Report of 11 cases and review of the literature. J Clin Gastroenterol. 1991;13:135–41.

    Article  PubMed  CAS  Google Scholar 

  4. Brenner B, Tang LH, Klimstra DS, Kelsen DP. Small-cell carcinomas of the gastrointestinal tract: a review. J Clin Oncol. 2004;22:2730–9.

    Article  PubMed  Google Scholar 

  5. Chin K, Baba S, Hosaka H, Ishiyama A, Mizunuma N, Shinozaki E, et al. Irinotecan plus cisplatin for therapy of small-cell carcinoma of the esophagus: report of 12 cases from single institution experience. Jpn J Clin Oncol. 2008;38:426–31.

    Article  PubMed  Google Scholar 

  6. Yana T, Negoro S, Takada M, Yokota S, Takada Y, Sugiura T, et al. Phase II study of amrubicin in previously untreated patients with extensive-disease small cell lung cancer: West Japan Thoracic Oncology Group (WJTOG) study. Invest New Drugs. 2007;25:253–8.

    Article  PubMed  CAS  Google Scholar 

  7. Inoue A, Sugawara S, Yamazaki K, Maemondo M, Suzuki T, Gomi K, et al. Randomized phase II trial comparing amrubicin with topotecan in patients with previously treated small-cell lung cancer: North Japan Lung Cancer Study Group Trial 0402. J Clin Oncol. 2008;26:5401–6.

    Article  PubMed  CAS  Google Scholar 

  8. Jotte R, Conkling P, Reynolds C, Galsky MD, Klein L, Fitzgibbons JF, et al. Randomized phase II trial of single-agent amrubicin or topotecan as second-line treatment in patients with small-cell lung cancer sensitive to first-line platinum-based chemotherapy. J Clin Oncol. 2011;29:287–93.

    Article  PubMed  CAS  Google Scholar 

  9. Ettinger DS, Jotte R, Lorigan P, Gupta V, Garbo L, Alemany C, et al. Phase II study of amrubicin as second-line therapy in patients with platinum-refractory small-cell lung cancer. J Clin Oncol. 2010;28:2598–603.

    Article  PubMed  Google Scholar 

  10. Walenkamp AM, Sonke GS, Sleijfer DT. Clinical and therapeutic aspects of extrapulmonary small cell carcinoma. Cancer Treat Rev. 2009;35:228–36.

    Article  PubMed  CAS  Google Scholar 

  11. Medgyesy CD, Wolff RA, Putnam JB Jr, Ajani JA. Small cell carcinoma of the esophagus: the University of Texas M.D. Anderson Cancer Center experience and literature review. Cancer (Phila). 2000;88:262–7.

    Article  CAS  Google Scholar 

  12. Huncharek M, Muscat J. Small cell carcinoma of the esophagus. The Massachusetts General Hospital experience, 1978 to 1993. Chest 1995;107:179–181.

    Google Scholar 

  13. Ku GY, Minsky BD, Rusch VW, Bains M, Kelsen DP, Ilson DH. Small-cell carcinoma of the esophagus and gastroesophageal junction: review of the Memorial Sloan-Kettering experience. Ann Oncol. 2008;19:533–7.

    Article  PubMed  CAS  Google Scholar 

  14. Noda K, Nishiwaki Y, Kawahara M, Negoro S, Sugiura T, Yokoyama A, et al. Irinotecan plus cisplatin compared with etoposide plus cisplatin for extensive small-cell lung cancer. N Engl J Med. 2002;346:85–91.

    Article  PubMed  CAS  Google Scholar 

  15. Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer. 2009;45:228–247

    Article  PubMed  CAS  Google Scholar 

  16. Hanada M, Mizuno S, Fukushima A, Saito Y, Noguchi T, Yamaoka T. A new antitumor agent amrubicin induces cell growth inhibition by stabilizing topoisomerase II-DNA complex. Jpn J Cancer Res. 1998;89:1229–38.

    Article  PubMed  CAS  Google Scholar 

  17. Onoda S, Masuda N, Seto T, Eguchi K, Takiguchi Y, Isobe H, et al. Phase II trial of amrubicin for treatment of refractory or relapsed small-cell lung cancer: Thoracic Oncology Research Group Study 0301. J Clin Oncol. 2006;24:5448–53.

    Article  PubMed  CAS  Google Scholar 

  18. Kobayashi M, Matsui K, Iwamoto Y, Ebi N, Oizumi S, Takeda K, et al. Phase II study of sequential triplet chemotherapy, irinotecan and cisplatin followed by amrubicin, in patients with extensive-stage small cell lung cancer: West Japan Thoracic Oncology Group Study 0301. J Thorac Oncol. 2010;5:1075–80.

    PubMed  Google Scholar 

  19. Isobe T, Yanai S, Kusaba H, Yada S, Kuroda Y, Tamiya S, et al. Effective monotherapy with amrubicin for a refractory extrapulmonary small-cell carcinoma of the liver. Case Rep Med. 2009;2009:538081.

    PubMed  Google Scholar 

  20. Katou M, Soga N, Onishi T, Arima K, Sugimura Y. Small cell carcinoma of the prostate treated with amrubicin. Int J Clin Oncol. 2008;13:169–72.

    Article  PubMed  Google Scholar 

  21. Asayama M, Fuse N, Yoshino T, Yano T, Tahara M, Doi T, et al. Amrubicin for the treatment of neuroendocrine carcinoma of the gastrointestinal tract: a retrospective analysis of five cases. Cancer Chemother Pharmacol. 2011;68:1325–1330.

    Google Scholar 

  22. Auperin A, Arriagada R, Pignon JP, Le Pechoux C, Gregor A, Stephens RJ, et al. Prophylactic cranial irradiation for patients with small-cell lung cancer in complete remission. Prophylactic Cranial Irradiation Overview Collaborative Group. N Engl J Med. 1999;341:476–84.

    Article  PubMed  CAS  Google Scholar 

  23. Slotman B, Faivre-Finn C, Kramer G, Rankin E, Snee M, Hatton M, et al. Prophylactic cranial irradiation in extensive small-cell lung cancer. N Engl J Med. 2007;357:664–72.

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Keisuke Aiba.

About this article

Cite this article

Nagasaki, E., Yuda, M., Tanishima, Y. et al. Complete response of esophageal small cell carcinoma amrubicin treatment. J Infect Chemother 19, 770–775 (2013). https://doi.org/10.1007/s10156-012-0510-8

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10156-012-0510-8

Keywords

Navigation